Moderna, Inc.
MRNA
Rangering i aksjer
#279
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Aksjekurs
$214.62
Sist synkronisert: 2026-10-16
Markedsverdi
$85.68B
Endring (1 dag)
-9.25%
Endring (1 år)
725.14%
Land
US
Handel Moderna, Inc. (MRNA)
Kategori
Healthcare
Driftsmargin for Moderna, Inc. (MRNA)
Driftsmargin per October 2026 TTM: -149.01%
Ifølge Moderna, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) -149.01%. Ved slutten av 2023 hadde selskapet en driftsmargin på -61.90%.
Historikk for driftsmargin for Moderna, Inc. fra 2016 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | -149.01% | 20.83% |
| 2024 | -123.32% | 99.22% |
| 2023 | -61.90% | -224.02% |
| 2022 | 49.91% | -33.43% |
| 2021 | 74.97% | -178.92% |
| 2020 | -94.99% | -89.52% |
| 2019 | -906.38% | 161.11% |
| 2018 | -347.13% | 165.25% |
| 2017 | -130.87% | -36.61% |
| 2016 | -206.44% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -100.26% |
US
|
|
| 25.57% | -100.17% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.19% |
NL
|
|
| 31.23% | -100.21% |
BE
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.